Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.61−0.32 (-16.58%)
Close on Nov 12, 2026Market cap $313.17MP/E –Yield –
Altimmune profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Altimmune's profit margin for the twelve months ending Dec 31, 2025 was -214861.0%. For fiscal 2025 it was -214861.0%, against -475295.0% the year before. The highest annual figure on record is -15.6% in fiscal 2011.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -214861.0% | +260434.0 |
| FY2024 | Dec 31, 2024 | -475295.0% | −454532.8 |
| FY2023 | Dec 31, 2023 | -20762.2% | −18560.6 |
| FY2021 | Dec 31, 2021 | -2201.6% | −1602.4 |
| FY2020 | Dec 31, 2020 | -599.2% | −245.5 |
| FY2019 | Dec 31, 2019 | -353.7% | +25.4 |
| FY2018 | Dec 31, 2018 | -379.2% | +53.2 |
| FY2017 | Dec 31, 2017 | -432.3% | −89.7 |
| FY2016 | Dec 31, 2016 | -342.6% | −326.9 |
| FY2011 | Dec 31, 2011 | -15.6% | +150.3 |
| FY2010 | Dec 31, 2010 | -166.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -105223.1% | +358376.9 |
| Q3 FY2025 | Sep 30, 2025 | -380280.0% | +76620.0 |
| Q2 FY2025 | Jun 30, 2025 | -442920.0% | +49880.0 |
| Q1 FY2025 | Mar 31, 2025 | -391500.0% | +96380.0 |
| Q4 FY2024 | Dec 31, 2024 | -463600.0% | −378083.8 |
| Q3 FY2024 | Sep 30, 2024 | -456900.0% | −451189.8 |
| Q2 FY2024 | Jun 30, 2024 | -492800.0% | −225116.7 |
| Q1 FY2024 | Mar 31, 2024 | -487880.0% | −392289.5 |
| Q4 FY2023 | Dec 31, 2023 | -85516.2% | +1090283.8 |
| Q3 FY2023 | Sep 30, 2023 | -5710.2% | +245627.3 |
| Q2 FY2023 | Jun 30, 2023 | -267683.3% | −206964.6 |
| Q1 FY2023 | Mar 31, 2023 | -95590.5% | −94861.5 |
| Q3 FY2022 | Sep 30, 2022 | -1175800.0% | −1154591.1 |
| Q2 FY2022 | Jun 30, 2022 | -251337.5% | −233215.6 |
| Q1 FY2022 | Mar 31, 2022 | -60718.8% | −58945.0 |
| Q4 FY2021 | Dec 31, 2021 | -729.0% | −269.7 |
| Q3 FY2021 | Sep 30, 2021 | -21208.9% | −20604.0 |
| Q2 FY2021 | Jun 30, 2021 | -18121.9% | −15798.4 |
| Q1 FY2021 | Mar 31, 2021 | -1773.7% | −1598.1 |
| Q4 FY2020 | Dec 31, 2020 | -459.3% | +252.2 |
| Q3 FY2020 | Sep 30, 2020 | -604.8% | +1093.9 |
| Q2 FY2020 | Jun 30, 2020 | -2323.5% | −2115.2 |
| Q1 FY2020 | Mar 31, 2020 | -175.6% | −104.6 |
| Q4 FY2019 | Dec 31, 2019 | -711.5% | +235.3 |
| Q3 FY2019 | Sep 30, 2019 | -1698.7% | −1609.5 |
| Q2 FY2019 | Jun 30, 2019 | -208.3% | +169.8 |
| Q1 FY2019 | Mar 31, 2019 | -71.0% | +47.0 |
| Q4 FY2018 | Dec 31, 2018 | -946.7% | −632.3 |
| Q3 FY2018 | Sep 30, 2018 | -89.2% | +562.0 |
| Q2 FY2018 | Jun 30, 2018 | -378.1% | −275.7 |
| Q1 FY2018 | Mar 31, 2018 | -117.9% | +1410.5 |
| Q4 FY2017 | Dec 31, 2017 | -314.4% | −7489.9 |
| Q3 FY2017 | Sep 30, 2017 | -651.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -102.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -1528.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 7175.5% | – |
See a number that looks wrong?